Why the study?
Does AZD1305 have a lower proarrhythmic potential compared to dofetilide in methoxamine-sensitized rabbits?
Population
Methoxamine-sensitized rabbits in vivo and in vitro whole cell patch-clamp models
Comparison
AZD1305 (novel combined ion channel blocker) vs Dofetilide (selective IKr blocker) and saline
Design
Preclinical
Authors
Loading...
AZD1305 may offer lower TdP risk than dofetilide in rabbits; leaves open translation to patients and needs clinical trials.
Does AZD1305 have a lower proarrhythmic potential compared to dofetilide in methoxamine-sensitized rabbits?
AZD1305 is a combined ion channel blocker that delays repolarization without increasing beat-by-beat variability or inducing TdP, and can suppress dofetilide-induced TdP in a rabbit model.
Carlsson et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: